

## ASX Announcement

### Notice under Section 708A(5)(e) of the Corporations Act

11 December 2025 – Racura Oncology Ltd (“Race”) advises that it has today issued 1,139,027 fully paid ordinary shares (**New Shares**) at an issue price of \$2.83 per New Share in accordance with the terms of the capital raising announced to the ASX on 9 December 2025.

The Company hereby gives notice under section 708A(5)(e) of the *Corporations Act 2001* (Cth) (“**Act**”) of the issue of the New Shares. The Act restricts the on-sale of securities issued without disclosure unless the sale is exempt under section 708 or 708A of the Act. By the Company giving this notice (“**Notice**”), a sale of the New Shares will fall within the exemption in section 708A(5) of the Act and they will be able to be traded immediately.

For the purposes of section 708A(6) of the Act, the Company gives notice that:

- (a) the New Shares were issued without disclosure to investors under Part 6D.2 of the Act;
- (b) this Notice is being given under section 708A(5)(e) of the Act;
- (c) as at the date of this Notice the Company has complied with:
  - (i) the provisions of Chapter 2M of the Act, as they apply to the Company; and
  - (ii) sections 674 and 674A of the Act; and
- (d) as at the date of this Notice there is no information that is ‘excluded information’ defined in section 708A(7) of the Act and which is required to be disclosed by the Company in accordance with section 708A(8) of the Act.

-ENDS-

### About Racura Oncology (ASX: RAC)

Racura Oncology (ASX: RAC) is a Phase 3 clinical biopharmaceutical company with a dedicated mission to be at the heart of cancer care.

Racura’s lead asset, RCDS1 (E,E-bisantrene), is a small molecule anticancer agent that primarily functions via G4-DNA & RNA binding, leading to potent inhibition of the important cancer growth regulator MYC. RCDS1 has demonstrated therapeutic activity in cancer patients with a well characterised safety profile. Recent discoveries made by Racura have enabled composition of matter IP filings that provide for 20 years of patent protection over RCDS1.

Racura is advancing a proprietary formulation of RCDS1 (RC220) to address the high unmet needs of patients across multiple oncology indications, with Phase 3 clinical programs in acute myeloid leukaemia (AML), a Phase 1a/b program in mutant epidermal growth factor receptor non-small cell lung cancer (EGFRm NSCLC), and a Phase 1a/b program in combination with the anthracycline doxorubicin, where we aim to deliver both cardioprotection and enhanced anticancer activity for solid tumour patients.

Racura Oncology has collaborated with Astex, MD Anderson, Sheba City of Health, UNC School of Medicine, University of Wollongong and University of Newcastle. Racura is actively exploring partnerships, licence agreements or a commercial merger and acquisition to accelerate access to RC220 for patients with cancer across the world. Learn more at [www.racuraoncology.com](http://www.racuraoncology.com).

If you have any questions on this announcement, or any past Racura Oncology announcements please visit our [Interactive Announcements](#) page.

*Racura encourages all investors to go paperless by registering their details with the Company's share registry, Automic Registry Services, at [www.automicgroup.com.au](http://www.automicgroup.com.au).*

**Release authorised by:**

Board of Racura Oncology  
[info@racuraoncology.com](mailto:info@racuraoncology.com)

**Media contact:**

Cherie Hartley +61 418 737 020  
[cherie.hartley@irdepartment.com.au](mailto:cherie.hartley@irdepartment.com.au)